骨肉瘤的免疫治疗进展  

Progress of Immunotherapy on Osteosarcoma

作　　者：郭中华 董爽[2] 欧武陵[2] GUO Zhonghua;DONG Shuang;OU Wuling(Department of Bone Surgery,the People's Hospital of Dongxihu District,Wuhan City,Wuhan 430040,China;Department of Oncology,Hubei Cancer Hospital,Wuhan 430079,China)

机构地区：[1]武汉市东西湖区人民医院骨外科,武汉430040 [2]湖北省肿瘤医院胸部肿瘤内科,武汉430079

出　　处：《医药导报》2020年第8期1089-1092,共4页Herald of Medicine

摘　　要：骨肉瘤是最常见的骨原发性恶性肿瘤,手术是早期骨肉瘤的主要治疗方式,伴随新辅助化疗的应用,患者总体生存率显著提高。但是晚期转移性骨肉瘤,治疗手段仍十分有限,治疗效果不理想,所以仍需发展新的骨肉瘤系统治疗方法。自19世纪80年代以来,各种免疫疗法已被用于骨肉瘤患者,一些患者对治疗产生反应,总体疗效甚微。近年来,免疫治疗进展迅速,已被广泛应用于多种恶性肿瘤。尽管目前关于骨肉瘤免疫治疗的报道有限,但免疫治疗被认为是治疗骨肉瘤的一种有前途的选择。该文围绕免疫检查点抑制剂、T细胞工程探讨了免疫疗法在骨肉瘤中的应用,并对其在骨肉瘤中的治疗潜力进行了讨论。Osteosarcoma(OS)is the most common primary malignant bone tumor.Surgery is the primary therapeutic approach in the treatment of early OS.With the benefits of neoadjuvant chemotherapy,the outcomes for the osteosarcoma treatments have improved significantly.However,the treatment and prognosis of metastatic or unresectable osteosarcomas were still unsatisfactory.Thus,the development of novel systemic therapies for osteosarcoma to improve the prognosis was needed.Since the 1980s,various immunotherapies have been utilized in patients with osteosarcoma and favorable response for some patients was observed after the treatment.However,the overall response rate was low.Immunotherapy has developed rapidly in recent years,and immunotherapy including immune checkpoint inhibitors and engineered T cells has been utilized in patients with many malignancies.Although there were limited reports of immunotherapies for osteosarcoma,immunotherapy was still thought to be a promising treatment option for osteosarcoma.In this review,an overview of various immunotherapies for osteosarcoma is provided and their potentials are discussed.

关 键 词：免疫检查点抑制剂 骨肉瘤 免疫治疗 T细胞工程 

分 类 号：R979.19[医药卫生—药品] R738.1[医药卫生—药学]